Radiotherapy in Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 144
Special Issue Editor
Interests: anal cancer; basal cell carcinoma; colon cancer; esophageal cancer; liver cancer; Merkel cell carcinoma; pancreatic cancer; rectal cancer; squamous cell carcinoma; stomach (gastric) cancer
Special Issue Information
Dear Colleagues,
Melanoma continues to steadily rise in prevalence, accounts for the majority of skin-cancer-related deaths, and remains a major public health problem. Historically, melanoma was thought to be relatively radiation therapy-resistant, and radiation therapy was thought to be of little use in treating melanoma. However, a growing body of research suggests the usefulness of especially hypo-fractionated and ablative radiation therapy in improving key outcomes. Although surgery remains the mainstay of treatment and immunotherapy has altered the treatment paradigm landscape, radiation therapy may be considered as an adjuvant, consolidative, definitive, or neoadjuvant treatment in some specific patient populations with melanoma. The purpose of this Special Issue is to examine the available data informing the use of radiation therapy in melanoma and to ultimately identify the melanoma patient populations who will derive benefit from radiation therapy.
Dr. Evan Wuthrick
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- radiotherapy
- neoadjuvant treatment
